Dharamshila Narayana Superspeciality Hospital

Patient Helpline 186-0208-0208

International Patient +91-9899414150

Mail Us contact@dhrc.in

Text Size

Dr. Sarita Rani Jaiswal

Dr. Sarita Rani Jaiswal - Best Haematologist in New Delhi
  • Consultant BMT and Haematology
Schedule An Appointment

Professional Qualifications

  • B.Sc., MBBS, MD, Fellowship in Critical Care Medicine
  • Fellowship in BMT (Italy)
  • Fellowship as a Visiting Physician at FHCRC, Seattle, USA

International Memberships

  • American Society Of Blood And Marrow Transplantation (ASBMT)
  • American Society Of Hematology
  • European Hematology Association (EHA)
  • Asia Pacific Hematology Consortium (APHCON)

Brief Profile of Dr. Sarita Jaiswal

Dr Sarita Jaiswal is the lead consultant for the Haploidentical BMT at Dharamshila Hospital and Research Centre. Dr Sarita trained in Internal Medicine, Critical Care Medicine and Pathology before initiating her career in Hemato-Oncology and BMT. Dr. Sarita did her fellowships in BMT Italy at University of Parma under Prof Franco Aversa and San Martino Hospital at Genova under Prof Andrea Bacigalupo. Dr Sarita also received a fellowship as a Visiting Physician at Fred Hutchinson Cancer Research Centre, Seattle, USA in 2013. Dr. Sarita Jaiswal has also trained exclusively in TCRalfabeta depleted Haploidentical BMT under Prof Aversa, who is a pioneer in this field. Dr. Sarita has been awarded the ESH-EBMT scholarship for her work in Haploidentical BMT. Since her return from USA, she has been instrumental in setting up a comprehensive haploidentical BMT program at Dharamshila Hospital. The program is one of its kind in India with a dedicated patient-care wing as well as basic research facilities. 

Dr Sarita and the team has carried out over 60 haploidentical BMT in the last two and half years with an impressive outcome in most difficult cases of refractory leukemia, lymphoma and  severe aplastic anemia with a disease-free-survival of over 70% in malignant diseases and over 80% in non-malignant diseases. The clinical and basic research carried out by Dr Jaiswal and her team has won accolades internationally. Dr Sarita has been invited for oral presentation of her work at the BMT Tandem Meetings in the USA for 3 consecutive years from 2015 onwards.

Her major area of research is on post-transplant immunotherapy and prevention of GVHD following haploidentical BMT. This has led to some novel developments in this field. Dr Sarita has had over 50 international publications and presentations in the last 3 years. The group has recently started a clinical trial on haploidentical BMT in thalassemia and sickle cell anemia.

In addition, Dr Sarita has major interest in management of acute leukemia in children and myeloproliferative disorders.

Academic Highlights

Guest Editor for special issue on Haploidentical Transplantation-Advances in Hematology . Peer Reviewer for BMT journal, BBMT etc

Presentations

  • Jaiswal S et al. Contrasting Patterns of Alloreactivity Amongst Malignant and Nonmalignant Diseases Receiving Haploidentical PBSC GRAFT and Post-Transplant Cyclophosphamide. (Poster no 473). 2013 BMT tandem meeting.
  • Jaiswal S et al. Persistently High GAM Levels Are Associated with Nonrelapse Mortality in HCT Recipients Irrespective of Invasive Aspergillosis: A Prospective Cohort Study.  (Poster no 305). 2013 BMT tandem meeting.
  • Jaiswal S et al. Second Haploidentical PBSC Transplantation From the Same Donor After Early Relapse without Gvhd in Patients with Acute Leukemia.  (Poster no 474). 2013 BMT tandem meeting.
  • Jaiswal S et al. Is Haploidentical Family Donor Transplantation The Best Form Of Alternative Donor HCT In Developing Countries? BTG 2013, Hongkong.
  • Jaiswal S. Is Haploidentical Family Donor Transplantation The Best Form Of Alternative Donor HCT In Developing Countries? (ORAL PRESENTATION) ESH EBMT TRAINING COURSE ON HCT, ITALY, APRIL 2013.
  • Jaiswal S. NK Alloreactive Donor Is Associated With Reduced Relapse In Refractory AML But High Non-relpase Mortality In Patients With Aplastic Anemia Following T-Replete Haploidentical PBSCT With Post Transplant. 18th Congress of EHA, 2013.
  • Jaiswal S et al. Comparable Outcome Of Haploidentical And Matched Sibling Donor Peripheral Blood Stem Cell Transplantation For High Risk Aplastic Anemia. 1st International Workup on Haploidentical Transplantation, 2013.
  • Jaiswal S et al. Comparable Outcome Of Haploidentical And Matched Sibling Donor Peripheral Blood Stem Cell Transplantation Following Myeloablative Conditioning For Poor Risk Acute Myeloid Leukemia. 1st International Workup on Haploidentical Transplantation, 2013.
  • Jaiswal S. Natural Killer Cells: A New Weapon in The Armamentarium. National Cancer Congress, 2014, DHRC, Delhi, 2014.
  • Jaiswal S et al. Outcome Of Haploidentical PBSC Transplantation For High Risk Aplastic Anemia With Post-Transplant Cyclophosphamide Is Similar To Matched Sibling PBSCT And Depends On Choice Of Donors: Adverse Effect Of Natural Killer Cell Alloreactivity. 40th Annual Meeting of the European Society for Blood and Marrow Transplantation: April 2014 .Milan, Italy.
  • Jaiswal S et al. Comparable Outcome Of Haploidentical And Matched Sibling Donor Peripheral Blood Stem Cell Transplantation Following Myeloablative Conditioning For Poor Risk Acute Myeloid Leukemia.40th Annual Meeting of the European Society for Blood and Marrow Transplantation: April 2014 .Milan, Italy
  • Jaiswal S et al. Impact Of Natural Killer (Nk) Cell Kir Ligand Mismatch And B Score On The Outcome Of Haploidentical Transplantation With Posttransplantation Cyclophosphamide (Ptcy) In Aplastic Anemia. 19th Congress of the European Hematology Association. April 2014 .Milan, Italy.
  • Jaiswal S et al. Impact of natural killer (NK) cell KIR ligand mismatch and B score on the outcome of haploidentical transplantation with post-transplantation cyclophosphamide (PTCY) in aplastic anemia.  2nd Hematology Conference on Hematology & Blood Disorders, Baltimore, 2014.
  • Jaiswal SR, Sharma K, Chakrabarti S. Developing a Haploidentical Transplant Program: An Indian Experience.  Oral Presentation at  BMT Tandem Meeting, San Diego, 2015
  • Jaiswal S et al. Pretransplant Sirolimus Might Improve The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Patients with Severe Aplastic Anemia. BMT Tandem Meeting, San Diego, 2015
  • Jaiswal S et al. Natural Killer (NK) Cell And Natural Killer-T (NKT) Cell Infusion Immediately Following Posttransplant Cyclophosphamide (PTCY) To Improve The Outcome Of Haploidentical HSCT Following Nonmyeloablative Conditioning. 41st Annual Meeting of the European Society for Blood and Marrow Transplantation: March 2015.
  • Jaiswal S et al. Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Primary Refractory Acute Myeloid Leukemia.  57th ASH Annual Meeting and Exposition (December, 2015) in Orlando, FL
  • Jaiswal S et al.Early Donor Lymphocyte Infusion and NK Ligand Mismatched Donor Might Improve the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Following PTCY-Based Haploidentical PBSC Transplantation with Myeloablative Conditioning. Oral Presentation at  BMT Tandem Meeting, Hawaii, 2016.
  • Jaiswal S et al. Haploidentical Transplantation with PBSC Graft in Children: The Need to Look Beyond Post-Transplantation Cyclophosphamide In Younger Children.BMT Tandem Meeting, Hawaii, 2016.
  • Jaiswal S et al. Gut Colonization with Carbapenem Resistant Enterobactriaceae(CRE) Adversely Impacts The Outcome InPatients With Hematological Malignancies: Results Of A Prospective Surveillance Study. 57th ASH Annual Meeting and Exposition (December, 2016), San Diago, USA.
  • Jaiswal S et al. CD56 Enriched Donor Cell Infusion Following Post-Transplantation Cyclophosphamide and Cyclosporine Alone for Haploidentical PBSCT in Myeloid Malignancies Is Associated with Prompt Reconstitution of Mature NK Cells and Tregs with Reduced Incidence of aGVHD. Oral Presentation at BMT Tandem Meeting, Orlando,2017
  • Jaiswal S et al. T Cell Costimulation Blockade with Abatacept Along with Pre-Transplantation Sirolimus and Post-Transplantation Cyclophosphamide (PTCy) Promotes Early Recovery of Tregs and Reduces Early Alloreactivity after Haploidentical PBSCT for Severe Aplastic Anemia. Oral Presentation at BMT Tandem Meeting, Orlando,2017

Publications

  • Jaiswal S et al. Contrasting Patterns of Alloreactivity Amongst Malignant and Nonmalignant Diseases Receiving Haploidentical PBSC GRAFT and Post-Transplant Cyclophosphamide. BBMT. 2013; 19:S346
  • Jaiswal S et al. Persistently High GAM Levels Are Associated with Nonrelapse Mortality in HCT Recipients Irrespective of Invasive Aspergillosis: A Prospective Cohort Study.  . BBMT. 2013; 19:S264
  • Jaiswal S et al. Second Haploidentical PBSC Transplantation From the Same Donor After Early Relapse without Gvhd in Patients with Acute Leukemia.  BBMT. 2013; 19:S264.
  • Jaiswal S et al. Is Haploidentical Family Donor Transplantation The Best Form Of Alternative Donor HCT In Developing Countries? Leukemia & Lymphoma Jun 2013, Vol. 54, No. S1: 3–31
  • Jaiswal S. NK Alloreactive Donor Is Associated With Reduced Relapse In Refractory AML But High Nonrelpase Mortality In Patients With Aplastic Anemia Following T-Replete Haploidentical PBSCT With Post Transplant. HEMATOLOGICA; 2013: 98 (S1); 159
  • Jaiswal S, Chatterjee S, Chakrabarti S. Paternal Bone Marrow Infusion As Salvage Therapy For Severe Gvhd Following Maternal Haploidentical Transplantation Resulting In BiparentalChimersim. Int J Hematol, 2013; Oct;98(4):504-8. doi: 10.1007/s12185-013-1426-5.
  • Jaiswal S et al. Outcome Of Haploidentical Pbsc Transplantation For High Risk Aplastic Anemia With Post-Transplant Cyclophosphamide Is Similar To Matched Sibling Pbsct And Depends On Choice Of Donors: Adverse Effect Of Natural Killer Cell Alloreactivity. Bone Marrow Transplant; 2014: 49(S1):S121
  • Jaiswal S et al. Comparable Outcome Of Haploidentical And Matched Sibling Donor Peripheral Blood Stem Cell Transplantation Following Myeloablative Conditioning For Poor Risk Acute Myeloid Leukemia. Bone Marrow Transplant; 2014: 49(S1):S209.
  • Jaiswal S et al. Impact Of Natural Killer (Nk) Cell Kir Ligand Mismatch And B Score On The Outcome Of Haploidentical Transplantation With Posttransplantation Cyclophosphamide (Ptcy) In Aplastic Anemia. Hematologica; 2015:
  • Jaiswal S et al. Impact of natural killer (NK) cell KIR ligand mismatch and B score on the outcome of haploidentical transplantation with post-transplantation cyclophosphamide (PTCY) in aplastic anemia.  J Blood Disorders Transf 2014, 5:8.
  • Jaiswal SR, Sharma K, Chakrabarti S. Developing a Haploidentical Transplant Program: An Indian Experience. Biol.Blood Marrow Transplant. 2015; 21(2), S66.
  • Jaiswal S et al. Pretransplant Sirolimus Improves The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Patients with Severe Aplastic Anemia. Biol.Blood Marrow Transplant. 2015; 21(2), S159.
  • Jaiswal S et al. Pretransplant Sirolimus Might Improve The Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Patients with Severe Aplastic Anemia. Bone Marrow Transplant, 2015; 50: 873-875; advance online publication, March 23, 2015; doi:10.1038/bmt.2015.50
  • Jaiswal S et al. Natural Killer (NK) Cell And Natural Killer-T (NKT) Cell Infusion Immediately Following Posttransplant Cyclophosphamide (PTCY) To Improve The Outcome Of Haploidentical HSCT Following Nonmyeloablative Conditioning. Bone Marrow Transplant, 2015: 50: S312-S499; doi:10.1038/bmt.2015.30
  • Chakrabarti A, Jaiswal S, Chakrbarti S. Sirolimus As Long-Term Graft-Versus-Host-Disease Prophylaxis In Haploidentical Hematopoietic Stem Cell Transplant Recipients For Non-Malignant Disorders Is Associated With High Incidence Of Acneiform Lesions. Indian Journal of Dermatology, Year : 2015 | Volume:  60 | Issue Number:  6 | Page: 588-591.
  • Jaiswal S et al. Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide.  International Journal of Hematology 11/2015; DOI:10.1007/s12185-015-1905.
  • Jaiswal S et al.Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with a Fludarabine, Busulfan and Melphalan Based Conditioning. Biology of blood and marrow transplantation: 11/2015; DOI:10.1016/j.bbmt.2015.11.010
  • Jaiswal S et al. Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Primary Refractory Acute Myeloid Leukemia.Blood: 2015; 126 (23)
  • Jaiswal SR, Chakrabarti S. Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues. Adv.Hematol. 2016; 2016: 3467672
  • Jaiswal SR. Haploidentical Transplantation in Children with Unmanipulated PBSC Graft in Children: The Need to Look Beyond Post-Transplantation Cyclophosphamide In Younger Children. Ped Transplant. 2016. 20; 675–682.
  • Jaiswal SR, Chakrabarti S. Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemia: Early Hype or Sustained Enthusiasm. Clinics in Oncology. 2016; in press.
  • Jaiswal S et al. Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia Following Post-Transplantation Cyclophosphamide Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic GCSF-Mobilized Donor Lymphocyte Infusions. Biol Blood Marrow Transplant. 2016 Jul 25. pii: S1083-8791(16)30252-X. doi: 10.1016/j.bbmt.2016.07.016. [Epub ahead of print]
  • Jaiswal S et al. T Cell Costimulation Blockade For Hyperacute Steroid Refractory Graft Versus-Host Disease In Children Undergoing Haploidentical Transplantation. Transplant Immunol.  10.1016/j.trim.2016.08.009.
  • Jaiswal S et al. CD56 Enriched Donor Cell Infusion Following Post-Transplantation Cyclophosphamide for Haploidentical Transplantation of Advanced Myeloid Malignancies Is Associated With Prompt Reconstitution of Mature Natural Killer Cells and Regulatory T Cells with Reduced Incidence of Acute Graft Versus Host Disease: A Pilot Study. Cytotherapy (2017; in press)
  • Jaiswal S et al. Gut Colonization with Carbapenem Resistant Enterobactriaceae (CRE) Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of a Prospective Surveillance Study. Blood 128, no. 22 (2016): 2402. Accessed January 18, 2017. http://www.bloodjournal.org/content/128/22/2402.

Post Your Query

Call 186-0208-0208
Mon–Sat 9:00 AM to 6:00 PM IST
Quicklinks